BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:27 PM
 | 
Oct 02, 2012
 |  BC Extra  |  Clinical News

Abraxane meets endpoint in first-line metastatic melanoma

Celgene Corp. (NASDAQ:CELG) said Abraxane nab-paclitaxel met the primary endpoint of progression-free survival (PFS) vs. dacarbazine in the Phase III CA033 trial in 529 chemotherapy-naive...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >